The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
32
Administered IT
UZ Leuven
Leuven, Belgium
NOT_YET_RECRUITINGHeritage Medical Research Clinic
Calgary, Canada
NOT_YET_RECRUITINGNumber of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline Up to Week 96
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University Hospital - London Health Sciences Centre
London, Canada
McGill University Health Centre
Montreal, Canada
RECRUITINGSunnybrook Research Institute
Toronto, Canada
RECRUITINGUniversitätsklinikum Schleswig-Holstein
Lübeck, Germany
NOT_YET_RECRUITINGUniversitätsmedizin Rostock
Rostock, Germany
NOT_YET_RECRUITINGUniversitaetsklinikum Ulm
Ulm, Germany
NOT_YET_RECRUITINGUniversitair Medisch Centrum Utrecht
Utrecht, Netherlands
NOT_YET_RECRUITINGHospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Spain
NOT_YET_RECRUITING...and 1 more locations